Matchpoint Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $150M

  • Investors
  • 13

Matchpoint Therapeutics General Information

Description

Developer of precision small-molecule medicines intended to harness the power of covalency to transform the treatment of immune diseases. The company's advanced covalent exploration platform integrates advanced chemoproteomics, machine learning, and covalent chemistry library evolution, enabling medical professionals to probe deeper into the proteome to identify and scan for new binding sites on disease-causing proteins.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • One Kendall Square
  • Building 400 Suite 201
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • One Kendall Square
  • Building 400 Suite 201
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Matchpoint Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 07-Oct-2026 $150M Completed Generating Revenue
2. Early Stage VC (Series A) 14-Oct-2022 Completed Generating Revenue
1. Seed Round 01-Nov-2021 $30M $30M Completed Generating Revenue
To view Matchpoint Therapeutics’s complete valuation and funding history, request access »

Matchpoint Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B2
Series B1
Series A 99,406,386 $0.000010 8% $0.7 $0.7 1x $0.7 17.95%
Seed 25,006,873 $0.000010 8% $1.2 $1.2 1x $0.85 6.4%
To view Matchpoint Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Matchpoint Therapeutics Patents

Matchpoint Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4801492-A1 Pyrrolo-isoquinoline compounds and their use in therapy Pending 01-Nov-2023
WO-2025096869-A1 Pyrrolo-isoquinoline compounds and their use in therapy Inactive 01-Nov-2023
WO-2024229401-A2 Diazepino-thieno-quinoxaline compounds and their use in therapy Inactive 04-May-2023
WO-2024229401-A3 Diazepino-thieno-quinoxaline compounds and their use in therapy Inactive 04-May-2023
WO-2024044731-A1 Diazepino-thieno-quinoxaline compounds and their use in therapy Inactive 26-Aug-2022 A61P29/00
To view Matchpoint Therapeutics’s complete patent history, request access »

Matchpoint Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Matchpoint Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
BB Biotech Asset Manager Minority
BOLD Longevity Growth Growth/Expansion Minority
Invus (Private Equity) PE/Buyout Minority
Nextech Invest Venture Capital Minority
Norwest Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Matchpoint Therapeutics FAQs

  • When was Matchpoint Therapeutics founded?

    Matchpoint Therapeutics was founded in 2021.

  • Where is Matchpoint Therapeutics headquartered?

    Matchpoint Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Matchpoint Therapeutics?

    Matchpoint Therapeutics has 31 total employees.

  • What industry is Matchpoint Therapeutics in?

    Matchpoint Therapeutics’s primary industry is Biotechnology.

  • Is Matchpoint Therapeutics a private or public company?

    Matchpoint Therapeutics is a Private company.

  • What is the current valuation of Matchpoint Therapeutics?

    The current valuation of Matchpoint Therapeutics is .

  • What is Matchpoint Therapeutics’s current revenue?

    The current revenue for Matchpoint Therapeutics is .

  • How much funding has Matchpoint Therapeutics raised over time?

    Matchpoint Therapeutics has raised $250M.

  • Who are Matchpoint Therapeutics’s investors?

    BB Biotech, BOLD Longevity Growth, Invus (Private Equity), Nextech Invest, and Norwest are 5 of 13 investors who have invested in Matchpoint Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process